Testing a pill for non-alcoholic fatty liver disease
Part of Digestive system, Hormones & metabolism clinical trials.
This trial tests a diabetes drug called empagliflozin to see if it can reduce fat and inflammation in the liver in people with a specific type of fatty liver disease called NASH. It may help if you have NASH and either have type 2 diabetes or don't have it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with a type of fatty liver disease called NASH, confirmed by a liver biopsy within the last 3 months.
- You either have type 2 diabetes or you do not, but we will test for it.
- Your HbA1c (a blood sugar test) is less than or equal to 80 mmol/mol.
- If you could become pregnant, you must agree to use two reliable forms of birth control.
- You must not have certain other liver diseases, or heavy alcohol use (men: more than 2 drinks per day, women: more than 1 drink per day).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two diabetes pills (pioglitazone and empagliflozin) to see if they can reduce liver fat in people with type 2 diabetes and fatty liver disease. It may help if your diabetes is not well controlled and you have a fatty liver confirmed by a special ultrasound scan.
This trial studies whether erugliflozin can reduce liver fat and liver scarring (fibrosis) while also improving blood sugar in people with type 2 diabetes and fatty liver disease (NASH/NAFLD). It’s designed for people who haven’t used certain diabetes medicines like SGLT2 inhibitors or insulin before.
This study tests a medication called empagliflozin (a type of SGLT2 inhibitor) to see if it can help treat fatty liver disease in teenagers and young adults. It may improve liver health and help with weight management.
This study tests whether a medicine called henagliflozin can help reduce fat in the liver for people with type 2 diabetes and non-alcoholic fatty liver disease. It may help improve liver health and blood sugar control at the same time.
This study compares two medicines, empagliflozin and statins, to see which works better for people with fatty liver disease and related conditions like diabetes, obesity, and high cholesterol.
This trial tests a diabetes medication (SGLT2 inhibitor) to see if it can help treat non-alcoholic fatty liver disease. If you have fatty liver not caused by alcohol, you may be able to join.
Hear when a new Liver Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.